Biomonitoring of occupational exposure to cytostatic anticancer drugs

Reviews on Environmental Health

Volumn 12, Issue 1, 1997, Pages 43-58

  Bos, R P ^a   Sessink, P J M ^a,b  

^a RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^b Exposure Contr Monitoring Consult   (Netherlands)

Author keywords

Alkylating agents; Antineoplastic agents; Biological monitoring; Carcinogens; Occupational health

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYTOSTATIC AGENT; FLUOROURACIL; METHOTREXATE;

BIOLOGICAL MONITORING; DNA DAMAGE; HEALTH CARE PERSONNEL; HUMAN; MEDICAL LITERATURE; OCCUPATIONAL EXPOSURE; OCCUPATIONAL HEALTH; REVIEW; RISK ASSESSMENT; RISK FACTOR; CELL DEATH; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; ENVIRONMENTAL MONITORING; FEMALE; MALE; METHODOLOGY; OCCUPATIONAL DISEASE;

ANTINEOPLASTIC AGENTS; CELL DEATH; ENVIRONMENTAL MONITORING; FEMALE; HEALTH PERSONNEL; HUMANS; MALE; OCCUPATIONAL DISEASES; OCCUPATIONAL EXPOSURE;

EID: 0030610677     PISSN: 00487554     EISSN: None     Source Type: Journal    
DOI: 10.1515/REVEH.1997.12.1.43     Document Type: Review

References (104)

1. Black DJ, Livingston RB. Antineoplastic drugs in 1990. A review (part I). Drugs 1990; 39: 489-501.
2. Black DJ, Livingston RB. Antineoplastic drugs in 1990. A review (part II). Drugs 1990; 39: 652-673.
3. Sorsa M, Hemminki K, Vainio H. Occupational exposure to anticancer drugs - Potential and real hazards. Mut Res 1985; 154: 135-149.
4. Ferguson LR, Denny WA. Anticancer drugs: An underestimated risk or an underutilised resource in mutagenesis? Mutat Res 1995; 331: 1-26.
5. Ladik CF, Stoehr GP, Maurer MA. Precautionary measures in the preparation of antineoplastics. Am J Hosp Pharm 1980; 37: 1185-1186.
6. McDiarmid M, Egan T. Acute occupational exposure to antineoplastic agents. J Occup Med 1988; 30: 984-987.
7. Sotaniemi EA, Sutinen S, Arranto AJ, Sutinen S, Sotaniemi KA, Lehtola J, Pelkonen RO. Liver damage in nurses handling cytostatic agents. Acta Med Scand 1983; 214: 181-189.
8. IARC monographs on the evaluation of carcinogenic risk of chemicals to humans. Vol. 26. Some antineoplastic and immunosuppressive agents. Lyon, France: International Agency for Research on Cancer, 1981.
9. IARC scientific publications. Nr.78. Carcinogenicity of alkylating cytostatic drugs. Lyon, France: International Agency for Research on Cancer, 1986.
10. IARC monographs on the evaluation of carcinogenic risks to humans. Suppl.7. Lyon, France: International Agency for Research on Cancer, 1987.
11. Hemminki K, Kyyrönen, Lindbohm M-L. Spontaneous abortions and malformations in the offspring of nurses exposed to anaesthetic gases, cytostatic drugs, and other potential hazards in hospitals, based on registered information of outcome. J Epidemiol and Commun Health 1985; 39: 141-147.
12. Selevan SG, Lindbohm M-L, Hornng RW, Hemminki K. A study of occupational exposure to antineoplastic drugs and fetal loss in nurses. N Engl J Med 1985; 313: 1173-1178.
13. McDonald AD, McDonald JC, Armstrong B, Cherry NM, Côté R, LaVoie J, Nolin AD, Robert D. Congenital defects and work in pregnancy. Br J Ind Med 1988; 45: 581-588.
14. Snicker I, Caillard J-F, Collin R, Gout M, Poyen D, Hemon D. Risk of spontaneous abortion among nurses handling antineoplastic drugs. Scand J Work Environ Health 1990; 16: 102-107.
15. Taskinen H, Lindbohm M-L, Hemminki K. Spontaneous abortions among women working in the pharmaceutical industry. Br J Ind Med 1986; 43: 199-205.
16. Skov T, Maarup B, Olsen J, Rorth M, Winthereik H, Lynge E. Leukaemia and reproductive outcome among nurses handling antineoplastic drugs. Br J Ind Med 1992; 49: 855-861.
17. Shortridge LA, Lemasters GK, Valanis B, Hertzberg V. Menstrual cycles in nurses handling antineoplastic drugs. Cancer Nurs 1995; 18: 439-444.
18. Baker GL, Kahl LE, Zee BC, Stolzer BL, Agarwal AK, Medsger Jr TA. Malignancy following treatment of rheumatoid arthritis with cyclophosphamide. Long-term case-control follow-up study. Am J Med 1987; 83: 1-9.
19. Greene MH, Harris EL, Gershenson DM, Malhasian GD, Joseph Melton L, Dempo AJ, Bennet JM, Moloney WC, Boice JD. Melphalan may be a more potent leukomogen than cyclophosphamide. Ann Intern Med 1986; 105: 360-367.
20. ASHP. ASHP technical assistance bulletin on handling cytotoxic and hazardous drugs. American Society of Hospital Pharmacists. Am J Hosp Pharm 1990; 47: 1033-1049.
21. VIK. Richtlijn cytostatica/Guideline antineoplastic agents (in Dutch). Utrecht, The Netherlands: Vereniging van Integrale Kankercentra, 1992.
22. Skov T. Handling antineoplastic drugs in the European Community countries. Eur J Cancer Prev 1993; 2: 43.
23. IMS Holland Personal report. The Hague, The Netherlands: Instituut voor Medische Statistiek, 1989.
24. Colligan SA, Horstman SW. Permeation of cancer chemotherapeutic drugs through glove materials under static and flexic conditions. Appl Occup Environ Hyg 1990; 5: 848-852.
25. Sessink PJM, van de Kerkhof MCA, Anzion RBM, Noordhoek J, Bos RP. Environmental contamination and assessment of exposure to antineoplastic agents by determination of cyclophosphamide in urine of exposed pharmacy technicians. Skin absorption an important exposure route? Arch Environ Health 1994; 49: 165-169.
26. Anderson RW, Puckett Jr WH, Dana WJ, Nguyen TV, Theiss JC, Matney TS. Risk of handling injectable antineoplastic agents. Am J Hosp Pharm 1982; 39: 1881-1887.
27. Falck K. Application of the bacterial urinary mutagenicity assay in detection of exposure to genotoxic chemicals. Thesis. Sweden: University of Helsinki, 1982.
28. IKN/IKO. Richtlijnen voor net werken met en het toepassen van cytostatica/Guidelines for handling and application of antineoplastic agents (in Dutch). Groningen/Nijmegen, The Netherlands, Integraal Kankercentrum Noord/Integraal Kankercentrum Oost, 1986.
29. DeWerk Neal A, Wadden RA, Chiou WL. Exposure of hospital workers to airborne antineoplastic agents. Am J Hosp Pharm 1983; 40: 597-601.
30. Pyy L, Sorsa M, Hakala E. Ambient monitoring of cyclophosphamide in manufacture and hospitals. Am Ind Hyg Assoc J 1988; 49: 314-317.
31. Sorsa M, Pyy L, Salomaa S, Nylund L, Yager JW. Biological and environmental monitoring of occupational exposure to cyclophosphamide in industry and hospitals. Mut Res 1988; 204: 465-479.
32. Sorsa M, Pyy L. Exposure assessment of workers in the production of cyclophosphamide. Pol J Occup Med 1990. 3: 185-189.
33. McDiarmid MA, Egan T, Furio M, Bonacci M, Watts SR. Sampling for airborne fluorouracil in a hospital drug preparation area. Am J Hosp Pharm 1986; 43: 1942-1945.
34. Kleinberg ML, Quinn ML. Airborne drug levels in a laminar-flow hood. Am J Hosp Pharm 1981; 38: 1301-1303.
35. Friederich U, Molko F, Hofmann V, Scossa D, Hann D, Würgler FE, Senn HJ. Limitations of the salmonella/mammalian microsome assay (AMES-test) to determine occupational exposue to cytostatic drugs. Eur J Cancer Clin Oncol 1986; 22(5): 567-575.
36. Sessink PJM, Anzion, RBM, Broek van den PHH, Bos RP. Detection of contamination with antineoplastic agents in a hospital pharmacy department, Pharm Weekbl [Sci] 1992; 14: 16-22.
37. Sessink PJM, Boer KA, Scheefhals APH, Anzion RBM, Bos RP. Occupational exposure to antineoplastic agents at several departments in a hospital. Environmental contamination and excretion of cyclophosphamide and ifosfamide. Int Arch Occup Environ Health 1992; 64: 105-112.
38. Sessink PJM, Cerná M, Rǒssner P, Pastorková A, Bavarová H, Franková K, Anzion RBM, Bos RP. Urinary cyclophosphamide excretion and chromosomal aberation in peripheral blood lymphocytes after occupational exposure to antineoplastic agents. Mutat Res 1994; 309: 193-199.
39. Sessink PJM, Friemèl NSS, Anzion RBM, Bos RP. Biological and environmental monitoring of occupational exposure of pharmaceutical plant workers to methotrexate. Int Arch Occ Env Health 1994; 65: 401-403.
40. Sessink PJM, Timmermans JL, Anzion RBM, Bos RP. Assessment of occupational exposure of pharmaceutical plant workers to 5-fluorouracil. Determination of α-fluoro-β-alanine in urine. J Occup Med 1994; 36: 79-83.
41. Sessink PJM, de Roos HC, Pierik FH, Anzion RBM, Bos RP. Occupational exposure to cyclophosphamide of animal caretakers. J Occup Med 1993; 35: 47-52.
42. Maron DM, and Ames BN. Revised methods for the Salmonella mutagenicity test. Mutation Res 1983; 113: 173-215.
43. Bos RP, and Jongeneelen FJ, Nonselective and selective methods for biological monitoring of exposure to coal-tar products. In: Methods for detecting DNA damaging agents in humans; applications in cancer epidemiology and prevention. Eds., Bartsch et al. IARC Scientific Publications 89, 1988: pp 389-395.
44. Tuffnell PG, Cannon MT, Dong A, DeBoer G, Erlichman C. Limitation of urinary mutagen assays for monitoring occupational exposure to antineoplastic drugs. Am J Hosp Pharm 1986; 43: 344-348.
45. Barale R, Sozzi G, Toniolo P, Borghi O, Reali D, Loprieno N, Porta GD. Sister-chromatid exchanges in lymphocytes andmutagenicity in urine of nurses handling cytostatic drugs. Mut Res 1985; 157: 235-240.
46. Bos RP, Leenaars AO, Theuws JLG, Henderson PTH. Mutagenicity of urine from nurses handling cytostatic drugs, influence of smoking. Int Arch Occup Environ Health 1982; 50: 359-369.
47. Breed ASPM, ten Hoopen AJ, Theuws JLG, Bos RP. Cytostaticabereiding en toediening, een gezondheidsrisico voor verpleegkundigen? Tijdschrift voor Sociale Gezondheidszorg 1986; 64: 361-365.
48. Courtois YA, Beaubestre C, Benhamou S, Min S, Callais F, Sancho-Garnier H, Festy B. Détermination de la génotoxicité urinaire: application au dépistage de l'exposition tabagique et/ou professionelle. Ann Pharm Fr 1987; 45: 289-300.
49. Everson RB, Ratcliffe JM, Flack PM, Hoffman DM, Watanabe AS. Detection of low levels of urinary mutagen excretion by chemotherapy workers which was not related to occupational drug exposures. Cancer Res 1985; 45: 6487-6497.
50. Baker R, Arlauskas A, Bonin A, Angus D. Detection of mutagenic activity in human urine following fried pork or bacon meals. Cancer Lett 1982; 16: 81-89.
51. Sasson IM, Coleman DT, La Voie EJ, Hopffman D, Wynder EL. Mutagens in human urine: Effect of cigarette smoking and diet. Mutat Res 1983; 158: 149-157.
52. Gibson JF, Gompertz D, Hedworth-Whitty RB. Mutagenicity of urine from nurses handling cytotoxic drugs. The Lancet 1984; 100-101.
53. Fransman LG, van der Put MTH, van Rijckevorsel JLA, Bos RP, Evelo CTA. Verslag van het onderzoek naar de biootstelling aan parenterale (genotoxische) cytostatica bij werknemers in de gezondheidszorg. Rijks Bedrijfsgezondheids - en Bedrijfsveiligheidsdienst, 's Gravenhage, 1986.
54. Jagun O, Ryan M, Waldron HA. Urinary thioether excretion in nurses handling cytotoxic drugs. The Lancet 1982; 443-444.
55. Sarto F, Trevisan A, Tomanin R, Canova A, Fiorentino M. Chromosomal aberrations, sister chromatid exchanges, and urinary thioethers in nurses handling antineoplastic drugs. Am J Ind Med 1990; 18: 689-695.
56. Banyan S, Burgaz S, Karakaya AE. Urinary thioether excretion in nurses at an oncology department. J Clin Pharm Ther 1987; 12: 303-306.
57. Burgaz S, Özdamar YN, Karakaya AE. A signal assay for the detection of genotoxic compounds: Application on the urines of cancer patients on chemotherapy and of nurses handling cytotoxic drugs. Human Toxicol 1988; 7: 557-560.
58. Hirst M, Tse S, Mills DG, Levin L. Occupational exposure to cyclophosphamide. The Lancet 1984; 186-188.
59. Evelo CTA, Bos RP, Peters JGP, Henderson PTH. Urinary cyclophosphamide assay as a method for biological monitoring of occupational exposure to cyclophosphamide. Int Arch Occup Environ Health 1986; 58: 151-155.
60. Ensslin AS, Stoll Y, Pethran A, Pfaller A, Römmelt H, Fruhmann G. Biological monitoring of cyclophosphamide and ifosfamide in urine of hospital personnel occupationally exposed to cytostatic drugs. Occup Environ Med 1994; 51: 229-233.
61. Sessink PJM. Monitoring of occupational exposure to antineoplastic agents. Thesis. The Netherlands: University of Nijmegen, ISBN 90-803205-1, 1996.
62. Sessink PJM, Wittenhorst BCJ, Anzion RBM, Bos RP. Exposure of pharmacy technicians to antineoplastic agents; reevaluation after additional protective measures. Arch Environ Health, in press.
63. Ensslin AS, Pethran A, Schierl R, Fruhmann. Urinary platinum in hospital personnel occupationally exposed to platinum-containing antineoplastic drugs. Int Arch Occup Environ Health 1994; 65: 339-342.
64. Venitt S, Crofton-Sleigh C, Hunt J, Speechley V, Briggs K. Monitoring exposure of nursing and pharmacy personnel to cytotoxic drugs: Urinary mutation assays and urinary platinum as markers of absorption. The Lancet 1984; 74-77.
65. Mader RM, Rizovski B, Steger GG, Rainer H. Determination of methotrexate in human urine at nanomolar levels by high-performance liquid chromatography with column switching. J Chromatogr 1993; 613: 311-316.
66. Mader RM, Rizovski B, Steger GG, Wachter A, Kotz R, Rainer G. Exposure of oncologic nurses to methotrexate in the treatment of osteosarcoma. Arch Env Health 1996; 51: 310-314.
67. Pesce MA, Bodourian SH. Evaluation of a fluorescence polarization immunoassay procedure for quantitation of methotrexate. Ther Drug Monit 1986; 8: 115-121.
68. Chrysostomou A, Seshadri R, Morley AA. Mutation frequency in nurses and pharmacists working with cytotoxic drugs. Aust NZ J Med 1984; 14: 831-834.
69. Hüttner E, Mergner U, Braun R, Schöneich J. Increased frequency of 6-thioguanine-resistant lymphocytes in peripheral blood of workers employed in cyclophosphamide production. Mutation Res 1990; 243: 101-107.
70. Oesch F, Hengstler JG, Arand M, Fuchs J. 1995. Detection of primary DNA damage: applicability to biomonitoring of genotoxic occupational exposure and in clinical therapy. Pharmacogenetics 5 Spec No: S118-122.
71. Fuchs J, Hengstler JG, Jung D, Hilt G, Konietzko J, Oesch F. DNA damage in nurses handling antineoplastic agents. Mutat Res 1995; 342: 17-23.
72. Lassila O, Toivanen A, Nordman E. Immune function in nurses handling cytostatic drugs. The Lancet 1980; 482.
73. Sessink PJM, Verplanke AJW, Herber RFM, Bos RP. Occupational exposure to antineoplastic agents and parameters for renal dysfunction. Int Arch Occup Environ Health, in press.
74. Sessink PJM, Kroese ED, van Kranen HJ, Bos RP. Cancer risk assessment for health care workers occupationally exposed to cyclophosphamide. Int Arch Occup Environ Health 1995; 67: 317-323.
75. Falck K, Gröhn P, Sorsa M, Vainio H, Heinonen E, Holsti LR. Mutagenicity in urine of nurses handling cytostatic drugs. The Lancet 1979; 1250-1251.
76. Staiano N, Gallelli IF, Adamson RH, Thorgeirsson SS. Lack of mutagenic activity in urine from hospital pharmacists admixing antitumour drugs. The Lancet 1981; 615-616.
77. Wilson JP, Solimando DA. Antineoplastics: A safety hazard? Am J Hosp Pharm 1981; 38: 624.
78. Nguyen TV, Theiss JC, Matney TS. Exposure of pharmacy personnel to mutagenic antineoplastic drugs. Cancer Res 1982; 42: 4792-4796.
79. Theiss JC. Hospital personnel who handle anticancer drugs may face risks. JAMA 1982; 247: 11-12.
80. Hoffman DM. Lack of urine mutagenicity of nurses administering pharmacy prepared doses of antineoplastic agents. Am J IV Ther Clin Nutr 1983; 10: 28-31.
81. Kolmodin-Hedman B, Hartvig P, Sorsa M, Falck K. Occupational handling of cytostalic drugs. Arch Toxicol 1983; 54: 25-33.
82. Cloak MM, Connor ThH, Stevens KR, Theiss JC, Alt JM, et al. Occupational exposure of nursing personnel to antineoplastic agents. Oncol Nurs Forum 1985; 12: 33-39.
83. Benhamou S, Callais F, Sancho-Garnier H, Min S, Courtois YA, Festy B. Mutagenicity in urine from nurses handling cytostatic agents. Eur J Cancer Clin Oncol 1986; 22: 1489-1493.
84. Connor TH, Theiss JC, Anderson RW, Puckett WH, Matney TS. Reevaluation of urine mutagenicity of pharmacy personnel exposed to antineoplastic agents. Am J Hosp Pharm 1986; 43: 1236-1239.
85. Pohlová H, Cerná M, Rössner P. Chromosomal aberrations, SCE and urine mutagenicity in workers occupationally exposed to cytostatic drugs. Mut Res 1986; 174: 213-217.
86. Stücker I, Hirsch A, Doloy T, Bastie-Sigeac I, Hemon D. Urine mutagenicity, chromosomal abnormalities and sister chromatid exchanges in lymphocytes of nurses handling cytostatic drugs. Int Arch Occup Environ Health 1986; 57: 195-205.
87. Caudell KA, Vredevoe DL, Dietrich MF, Caudell ThP, Hoban MJ, Block JB. Quantification of urinary mutagens in nurses during potential antineoplastic agent exposure. A pilot study with concurrent environmental and dietary control. Cancer Nursing 1988. 11:41-50.
88. Poyen D. Botta A, de Meo M, Gouvernet J, Dalivousi G, Mathias A, Dumenil G. Etude de la mutagénicité urinaire d'agents hospitaliers féminins: influence primordiale du tabagisme. Arhives des Maladies Professionelles de Médicine du Travail et de la Sécurité Sociale 1988; 49: 11-16.
89. Poyen D, DeMéo M, Botta A, Gouvernet J, Duménil G. Handling of cytostatic drugs and urine mutagenesis. Int Arch Occup Environ Health 1988; 61: 183-188.
90. Krepinsky A, Bryant DW, Davison L, Young B, Heddele J, McCalla DR, et al. Comparison of Three Assays for Genetic Effects of Antineoplastic Drugs on Cancer Patients and Their Nurses. Environ Mol Mutag 1990; 15: 83-92.
91. Thiringer G, Granung G, Holmén A, Högstedt B, Järvholm B, et al. Comparison of methods for the bio- monitoring of nurses handling antitumor drugs. Scand J Work Environ Health 1991; 17: 133-138.
92. DeMéo MP, Mérono S, DeBaille AD, Botta A, Laget M, Guiraud H, Duménil G. Monitoring exposure of hospital personnel handling cytostatic drugs and contaminated materials. Int Arch Occup Environ Health 1995; 66: 363-368.
93. Norppa H, Sorsa M, Vainio H, Gröhn P, Heinonen E, Holsti L, Nordman E. Increased sister chromatid exchange frequencies in lymphocytes of nurses handling cytostatic drugs. Scand J Work Environ Health 1980; 6: 299-301.
94. Waksvik H, Klepp O, Brigger A. Chromosome analyses of nurses handling cytostatic agents. Cancer Treat Rep 1981; 65: 607-610.
95. Szigeti M, Fekete G, Szollár J. The effect of regular cytostatic handling on the sister-chromatid exchanges in hospital nurses. Mut Res 1982; 97: 227.
96. Stiller A, Obe G, Boll I, Prebilla W. No elevation of the frequencies of chromosomal alterations as a consequence of handling cytostatic drugs. Analyses with peripheral blood and urine of hospital personnel. Mut Res 1983; 121: 253-259.
97. Nikula E, Kiviniitty K, Leisti J, Taskinen PJ. Chromosome aberrations in lymphocytes of nurses handling cytostatic agents. Scand J Work Environ Health 1984; 10: 71-74.
98. Jordan DK, Patil SR, Jochimsen PR, Lachenbruch PA, Corder MP. Sister chromatid exchange analysis in nurses handling antineoplastic drugs. Cancer Invest 1986. 4: 101-107.
99. Benhamou S, Pot-Deprun J, Sancho-Garnier H, Chouroulinkov I. Sister chromatid exchanges and chromosomal aberrations in lymphocytes of nurses handling cytostatic agents. Int J Cancer 1988; 41: 350-353.
100. Oestreicher U, Stephan G, Glatzel M. Chromosome and SCE analysis in peripheral lymphocytes of persons occupationally exposed to cytostatic drugs handled with and without use of safety covers. Mutat Res 1990; 242: 271-277.
101. Milkovic-Kraus S, Horvat D. Chromosomal abnormalities among nurses occupationally exposed to antieoplastic drugs. Am J Ind Med 1991; 19: 771-774.
102. Cooke J, Williams J, Morgan RJ, Cooke P, Calvert T. Use of cytogenetic methods to determine mutagenic changes in the blood of pharmacy personnel and nurses who handle cytotoxic agents. Am J Hosp Pharm 1991; 48: 1199-1205.
103. Sardas S, Gök S, Karakaya A. Sister chromatid exchanges in lymphocytes of nurses handling antineoplastic drugs. Toxicol Letters 1991; 55: 311-315.
104. Grummt T, Grummt H-J, Schott G. Chromosomal aberrations in peripheral lymphocytes of nurses and physicians handling antineoplastic drugs. Mutat Res 1993; 302: 19-24.